Medreich is a fully integrated pharmaceutical company with an established presence across the globe. The company is involved in the manufacturing and marketing range of pharmaceutical preparations in various dosage forms catering to diverse Therapeutic categories, across various geographies.
Medreich has state of the art Formulation Development centre housing competence to develop products with a focus on NDDS.
Medreich has in house capability to ensure regulatory compliance in regulated markets across the globe.
With a client base spread across 54 countries, the company is involved in manufacturing of formulations for multinationals like GSK, Pfizer, Sanofi Aventis, Wyeth, Adcock Ingram, Mylan, Actavis and many other customers.
With more than 2000 employees worldwide, Medreich has built a reputation for raising the bar on product quality while maintaining high standards of service levels.
Contact
Physical Address
14 Komatie Road
Emmarentia 2195
Postal Address
P.O. Box 421001
Fordsburg,
2033
South Africa
Tel: +27 11 433 0602
Fax: +27 86 633 7876
E-mail: mbodhania@medreich.co.za
Muhammad Bodhania, Managing Director of Medreich South Africa discusses potential strategic implications of the recent acquisition of Medreich by Meiji and the importance of local partnerships for global success. Can…
Medicines for Africa’s Lenias Hwenda reflects on Moderna’s recent decision not to go ahead with plans for a vaccine manufacturing facility in Kenya, and why local production remains crucial to…
Medicines for Africa’s Lenias Hwenda argues that the success of the much-talked-about African Medicines Agency hinges on a critical mass of African national regulators achieving WHO Level 3 maturity status.…
Writing in the February 2024 edition of the DIA Global Forum magazine, Verena Pfaffinger and Ilona Baraniak-Lang of PharmaLex examine how the drug shortages seen in the global south during…
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
Dr Benji Pretorius, the founder of Erada Technology Alliance and a malaria survivor himself, shares his insights into why the development of a truly effective malaria vaccine will only succeed…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Nevena Miletic of Roche and the IFPMA’s Africa Regulatory Network and Ian Hudson from the Bill and Melinda Gates…
The third and final piece in Lenias Hwenda of Medicines for Africa’s series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential…
The second in a three-part series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come (read part one…
In the first of a series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come, Lenias Hwenda of…
During the COVID-19 pandemic discussions around increasing access to medicines for low and middle-income countries (LMICs) were often centred on compulsory licensing. As a result, pharma companies were up in…
As part of a special focus on drug development and clinical research in Africa in February 2023’s DIA Global Forum magazine, Lisa Ursella Collins of Innomas Clinical Research, Leslie Sam…
Roughly half of Africa’s 1.1 billion people lack regular access to even the most essential medicines and most of Sub-Saharan Africa depends on imports which make up as much as…
See our Cookie Privacy Policy Here
